RecruitMe Clinical Trial

Measurement of NRX-101 Target Engagement in Bipolar Depression using the Glx biomarker and Magnetic Resonance Spectroscopy
MRI Effects of D-cycloserine & Lurasidone in Bipolar Depression
Sponsor:NeuroRx
Enrolling:Male and Female Patients
Age Range:Between 18 and 55 years old
IRB Number:7427
U.S. Government ID:NCT03402152
Contact: Vashti Wagner, CRC: 646-774-7627 / vashti.wagner@nyspi.columbia.edu
Additional Study Information:

We will evaluate the D-cycloserine (DCS) and lurasidone with MRI measurement of brain responses to DCS. DCS is a drug that works on the same brain receptor as ketamine. DCS is not approved by the FDA for bipolar depression. Study participants will receive a dose of lurasidone or placebo in one MRI and a dose of DCS in another, followed by an optional follow-up four week phase of lurasidone plus DCS. We hope to develop a better understanding of how these medications work. Participants should be currently depressed and be willing to stop their medications or not currently be taking any medications. Participation involves clinical assessments, taking medications, blood draws and up to 3 MRIs. Eligible individuals will be compensated up to $1100 and may receive up to 5 months of free doctor visits for medication-based treatment.

This study is closed
Investigator
Dr. Joshua Kantrowitz
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Vashti Wagner, CRC
Email: vashti.wagner@nyspi.columbia.edu
Phone: 646-774-7627